Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:INZY

Inozyme Pharma (INZY) Stock Price, News & Analysis

Inozyme Pharma logo

About Inozyme Pharma Stock (NASDAQ:INZY)

Advanced Chart

Key Stats

Today's Range
$4.00
$4.00
50-Day Range
$3.95
$4.00
52-Week Range
$0.72
$6.24
Volume
N/A
Average Volume
960,267 shs
Market Capitalization
$258.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.75
Consensus Rating
Hold

Company Overview

Receive INZY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inozyme Pharma and its competitors with MarketBeat's FREE daily newsletter.

INZY Stock News Headlines

Inozyme Pharma Inc News (INZY) - Investing.com
Alex’s “Next Magnificent Seven” stocks
The original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Magnificent Seven—seven stocks he believes could deliver similar gains in under six years. His full breakdown is now live.
Inozyme Pharma Inc Ordinary Shares
BMRN to Acquire Inozyme Pharma
See More Headlines

INZY Stock Analysis - Frequently Asked Questions

Inozyme Pharma, Inc. (NASDAQ:INZY) posted its quarterly earnings data on Wednesday, May, 14th. The company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.43) by $0.01.

Inozyme Pharma (INZY) raised $75 million in an IPO on Friday, July 24th 2020. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Cowen and Piper Sandler acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Top institutional investors of Inozyme Pharma include Alpine Associates Management Inc. (3.39%), Geode Capital Management LLC (1.89%), Credit Industriel ET Commercial (0.23%) and Credit Industriel ET Commercial (0.23%). Insiders that own company stock include Robert Lorne Hopfner, Pivotal Bioventure Partners Fu, Henric Bjorn Bjarke and Douglas A Treco.
View institutional ownership trends
.

Based on aggregate information from My MarketBeat watchlists, some other companies that Inozyme Pharma investors own include Salesforce (CRM), Home Depot (HD), Chevron (CVX), CocaCola (KO), Meta Platforms (META), QUALCOMM (QCOM) and AbbVie (ABBV).

Company Calendar

Last Earnings
5/14/2025
Today
8/09/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:INZY
CIK
1693011
Fax
N/A
Employees
50
Year Founded
N/A

Price Target and Rating

High Price Target
$23.00
Low Price Target
$4.00
Potential Upside/Downside
+193.8%
Consensus Rating
Hold
Rating Score (0-4)
2.44
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.69)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$102.02 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-159.93%
Return on Assets
-82.48%

Debt

Debt-to-Equity Ratio
0.65
Current Ratio
2.19
Quick Ratio
2.19

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.90 per share
Price / Book
4.44

Miscellaneous

Outstanding Shares
64,562,000
Free Float
56,698,000
Market Cap
$258.25 million
Optionable
Optionable
Beta
2.27

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:INZY) was last updated on 8/9/2025 by MarketBeat.com Staff
From Our Partners